The board of drug manufacturer Kahira Pharmaceuticals endorsed financial highlights for the two-month period from July 1 till August 31, 2014, indicating EGP 11.250 million net profit before tax, with 16.3% decline year-over-year from EGP 13.5 million.
Financial results for the fiscal year that ended on June 30, 2014 had shown EGP 41.1 million net profit, with a 23.9% decline compared with EGP 53.98 million a year earlier.
The company had posted EGP 50 million net profit before tax for the first nine months of FY13/14, with a rise by 8.9% compared with EGP 46 million in the same period a year earlier.